What is Immix Biopharma, Inc.'s share price?

Immix Biopharma, Inc. (IMMX) reported share price of $5.10 in Q4 2025.

What does share price mean?

The current market valuation of a single share of the company's common stock as determined by public exchange trading. It reflects investor sentiment regarding the company's clinical pipeline, management execution, and future growth prospects. This metric is the primary indicator of market capitalization and the cost of equity capital.

Immix Biopharma, Inc. IMMX Share Price

Share Price at other companies

Hercules CapitalHTGC

$14.77-23.1%

Bain Capital Specialty FinanceBCSF

$12.40-25.3%

Prospect CapitalPSEC

$25.000.0%

TecnoglassTGLS

$0.150.0%

Center BancorpCNOB

$22.97—

Independent Bank CorporationIBCP

$32.53-6.6%

Other financials

Income statement

See full

Operating income-$10.8M-131%

Net income-$10.1M-122%

EPS (diluted)-$0.18-20.0%

Balance sheet

See full

Cash & equivalents$79.3M+398%

Total debt$1.0M-2.0%

Total equity$84.4M+779%

Total assets$95.8M+382%

Cash flow

See full

Operating cash flow-$9.8M-483%

CapEx$32.5K-52.0%

Free cash flow-$9.9M-462%

Valuation

See full

Market cap$691.97M+1,008%

Enterprise value$613.75M+1,190%

Returns & leverage

See full

Return on equity-74.4%-18.6pp

Debt / equity0×-0.1×

Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharePrice.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s share price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immix Biopharma, Inc.'s share price?: Immix Biopharma, Inc. (IMMX) reported share price of $5.10 in Q4 2025.
What does share price mean?: The current market valuation of a single share of the company's common stock as determined by public exchange trading. It reflects investor sentiment regarding the company's clinical pipeline, management execution, and future growth prospects. This metric is the primary indicator of market capitalization and the cost of equity capital.